Glenmark starts Phase 3 trial for ovarian cancer ADC in India
India is first to enroll in a multi-country study for Trastuzumab rezetecan. The drug, in-licensed from Hengrui, excludes major markets like the US and Europe, limiting financial upside.
— 4 earlier stories on Glenmark Pharmaceuticals Ltd. →What's new
- Glenmark begins Phase 3 enrollment in India for its HER2-targeted ADC in platinum-resistant ovarian cancer.
- The trial will also enroll patients in Australia and South Korea to generate diverse data.
- Drug in-licensed from Hengrui Pharma in Sep 2025; commercial rights exclude US, EU, Japan.
Why this matters
The Phase 3 start is a routine clinical step for a large-cap pharma. With limited territory rights and no revenue forecasts disclosed, this is not a game-changer. It keeps the pipeline ticking but offers no near-term earnings trigger.
What we're watching
- Timeline for first patient data and any expansion to other licensed markets.
- Updates on Glenmark's margin guidance and Envafolimab launch, which saw recent cuts and delays.
- Potential partnership extensions to broaden the ADC's commercial reach.
The full read
Glenmark's subsidiary has started enrolling patients in India for a Phase 3 trial of Trastuzumab rezetecan, a HER2-targeted ADC for platinum-resistant ovarian cancer. India is the first of multiple planned countries (Australia and South Korea are next), and the data will supplement Hengrui's own Phase 3 in China. It's a clean execution step on a September 2025 in-license. What keeps this from being a headline event: Glenmark's commercial rights exclude the US, Europe, and Japan. The filing carries no revenue forecasts or market-size estimates. For a ₹60,797 cr pharma with recent margin cuts and a delayed Envafolimab launch, this trial moves the pipeline forward without moving the needle. It's a routine milestone. Nothing more.
Questions answered
- What is Trastuzumab rezetecan?
- It's a HER2-targeted antibody-drug conjugate in-licensed from Hengrui Pharma for certain territories. Glenmark is developing it for platinum-resistant ovarian cancer and possibly other indications.
- What makes this trial different from others?
- It's a multi-country Phase 3 that aligns with Hengrui's ongoing parent trial in China. India is the first to enroll, followed by Australia and South Korea, aiming for diverse patient data.
- What commercial rights does Glenmark have for this drug?
- Glenmark's rights exclude major markets: the US, Europe, and Japan, limiting the revenue potential. The drug is licensed for Glenmark's own territories only.
- Why is this not a major catalyst for Glenmark?
- Clinical trial progress is expected for in-licensed assets; no financial quantification or surprise element exists. With ₹60,797 cr market cap and no revenue forecasts, the impact on earnings is negligible near-term.
- When did Glenmark license this drug?
- The licensing agreement with Hengrui Pharma was announced in September 2025. The Phase 3 advancement is part of the planned development pathway.
Glenmark Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on GLENMARK →- 2 Jul 2026 · 8:37 AM IST Glenmark starts Phase 3 trial for ovarian cancer ADC in India
- 6d ago Glenmark gets six FDA observations at Goa plant; supply unaffected
- 25d ago Glenmark lands first new chemical entity in Europe with acne cream
- 31d ago Glenmark's transcript adds detail to its margin cut and Envafolimab delay
- 35d ago Glenmark cuts FY27 margin guidance to 21-22%, delays Envafolimab launch